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WHAT IS ALREADY KNOWN ON THIS TOPIC
Antidepressants might decrease platelet aggregation, while nonsteroidalanti-inflammatory drugs
(NSAIDs) may also inhibit platelet
function, so both may increase bleeding.1 While antidepressants and
NSAIDS are thought to increase gastrointestinal haemorrhage,1 there
are contradictory results on the risk of intracranial haemorrhage (ICH)
with the coprescription of antidepressants and NSAIDs in case control
and population studies.2 3 Antidepressants alone are not thought to
increase the risk of intracranial haemorrhage.4
METHODS OF THE STUDY
A nationwide cohort study of all healthcare insurance claims covering
all the population of Korea was carried out. The study examined healthcare
claims for people with depression started on antidepressants
(including monoamine oxidase inhibitors, buproprion, hypericin, tianeptin)
over a 4-year period (2009–2013). NSAIDs included selective inhibitors
of COX-2 but excluded low-dose aspirin. People prescribed an
antidepressant or a history of intracranial bleeding in the previous year,
taking more than one antidepressant at the index date and loss of data
at follow-up were excluded. Propensity scoring was used to match two
equal size samples of 2 072 613 patients starting antidepressants in
people already taking NSAIDs versus those taking antidepressants but
not NSAIDs. Matching was for age, gender, years of observation,
comorbidities associated with bleeding, severity of comorbidity and
other medication associated with bleeding. In total 1 023 607 (19.8%)
eligible patients were excluded from the propensity matched samples.
The sample was censored for the primary outcome of interest (hospital
admission for ICH within 30 days of being prescribed an antidepressant),
date switched to another antidepressant, date of discontinuation
of an antidepressant or the last date of the study. The incidence rate
per 1000 person years was calculated by dividing the number of ICH
events by the total number of person years at risk and multiplying the
result by 1000. Cox regression models (controlling for dementia, warfarin,
heparin and steroids) were used to estimate HRs for ICH with
time varying covariates in each the propensity-based matched cohort.
WHAT THIS PAPER ADDS
▸ The risk of ICH requiring hospitalisation was higher within 30 days
when antidepressants were combined with NSAIDs compared to
antidepressant use without NSAIDs (HR 1.6, 95% CI 1.32 to 1.85).
▸ There were no differences in risk of ICH between antidepressant
drug classes, comorbidities, additional medication nor types of ICH
(subarachnoid haemorrhage, intracerebral haemorrhage, other nontraumatic
intracerebral haemorrhage).
▸ The HR for concomitant use of NSAIDs was higher in males (2.6,
95% CI 1.93 to 3.42) than females (1.2, 95% CI 0.89 to 1.57).
LIMITATIONS
▸ Sample with very high rates of warfarin (57%), low-dose aspirin
(13%) and antithrombotic drugs (6%) so results are not generalisable
to patients not taking other drugs with the potential to cause
bleeding.
▸ There was incomplete and potentially biased assessment of
outcome with no assessment of community ICH and sudden death;
patients already taking NSAIDs may be more readily identified to be
at risk of bleeding so taken to hospital and scanned.
▸ No check on whether participants took antidepressants prescribed
to them and potential inaccuracy of coding within the claims data.
▸ Propensity scoring introduces selection bias by excluding 20% of
participants available for observation and may unleash hidden bias
due to latent unobserved variables. The last problem may be operating
with no control for history of depression and ICH more than
1 year before the observation period, both factors that are likely to
be considered by doctors in their decision-making. Moreover, the
propensity matching resulted in a slight excess in the NSAID and
antidepressant group on 16 of 17 the most common medical and
drug comorbidities that may be clinically related to each other and
therefore introducing further confounding in an observational study
already confounded by indication for AD and NSAIDs.
WHAT NEXT IN RESEARCH
▸ Repeat the study with improved modelling in a sample with and
without coprescription of warfarin or drugs causing bleeding and
with the inclusion of community ICH and sudden death.
▸ Carry out data mining studies in routine practice and a prospective
observational study in established cohorts.
DO THESE RESULTS CHANGE YOUR PRACTICE AND WHY?
Yes to a limited extent. Before starting patients with depression who
are taking NSAIDS with other drugs with the potential for bleeding,
careful review with physician or general practitioner colleagues of the
risk of bleeding in that patient and/or consideration of other nonantidepressant
approaches in selected patients at risk of bleeding.
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